System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Emmanuel Messas is an expert in Cardiology at Hôpital Européen Georges-Pompidou (France). As of October 2026, ScienceLeadR ranks Emmanuel Messas in the top 1% of experts worldwide for Embolism and Thrombosis. Emmanuel Messas has authored 335 publications, the most recent in 2026, and is an investigator in 22 clinical trials, 2 of them ongoing. SLR score: 1,614 (community average: 125). How the SLR is computed.

LeadR Profile

Emmanuel Messas Hôpital Européen Georges-Pompidou France
1 614 ScienceLeadR Reputation 1614

Unlock

Register Login
Network Map

Cardiology

Subspecialties: Medical Imaging - Public Health - Hematology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2001 - 2026
Source: PubMed

Hôpital Européen Georges-Pompidou

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 335

Citations

Citations: 21 403 1st author: 27 Last author: 83 Unique author: 13

Main journals

Eur Heart J 30
Circulation 19
J Am Coll Cardiol 14
Archives of cardiovascular diseases. Supplements 13
JMV-Journal de médecine vasculaire 12

Best Journals

Eur Heart J 9
N Engl J Med 5
Circulation 3

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Combined low-dose thoracic computed tomography and circulating tumor cell screening for cancer in ever smokers with peripheral arterial disease: A prospective multicenter cohort study.
PMID 42636547 — cells, lung, neoplastic cells, circulating, tomography, smokers, neoplasms, cohort studies, lung neoplasms, peripheral arterial disease, smoking		Lung Cancer20260
Prospective, Single-Arm Pivotal Study for the Treatment of Subjects With Severe Symptomatic Calcific Aortic Valve Stenosis Using the Valvosoft Noninvasive Ultrasound Therapy.
PMID 42574521 — constriction, pathologic, aortic valve stenosis, cardiovascular system, aortic valve, therapeutics, blood circulation		Circulation Top journal20260
Machine Learning for Cardiovascular Prevention Prescriptions: Real-World vs. Synthetic Data.
PMID 42174854 — medical informatics, prescriptions, machine learning, learning		Stud Health Technol Inform20260
The effects of aging on left ventricular diastolic function evaluated with 4D flow MRI: a novel approach using mitral velocity and propagation velocity measurements.
PMID 42061967 — research design, biophysics, aging		Physiol Meas20260
Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial.
PMID 41903215 — diabetes mellitus, cholesterol, ldl, stroke, myocardial infarction, atherosclerosis		JAMA Top journal20260

Clinical Studies 22

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 5 Sub-Investigator: 2

By phase:

N/A 11
Phase 3 10
Phase 4 1

By status:

Completed 18
Recruiting 3
Active not recruiting 1

By type:

Interventional 21
Observational 1

By Monocentric/Multicentric:

monocentric 9
multicentric2to4 0
multicentric5to9 0
multicentricup10 13

Main Topics

Cohort/Consortium Investigators 3

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
EASi PROTKT A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes high blood pressure and cardiovascular disease
2025-521188-11-00 — diabetes mellitus, hypertension, safety, blood, cardiovascular diseases, blood pressure, diabetes mellitus, type 2		Phase 3Recruiting2025
Duration of Dual Anti Platelet Therapy in Chronic Limb Threatening Ischemia after Distal Revascularization a randomized double blind trial
2025-524297-42-00 — dual anti-platelet therapy, peripheral arterial disease, therapeutics, blood platelets, ischemia		Phase 3Recruiting2026

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS